Huntington's Disease burdens caregivers in India, facing financial strain and limited support amid widespread underdiagnosis ...
The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.
Neurocrine Biosciences said on Monday its drug failed to meet the main goal in a late-stage clinical trial in patients with a type of disorder that disrupts the brain's ability to control muscles.
Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...
Analysts said the outcome is disappointing because there are no approved treatments for dyskinetic cerebral palsy, but the setback had little impact on Neurocrine's valuation.
A retired salesman took his own life after killing his wife after struggling to cope with her deteriorating condition from suspected Huntington's disease, an inquest has heard. The bodies of Michael ...
San Diego, USA-based Neurocrine Biosciences announced that its Phase III KINECT-DCP study evaluating the efficacy, safety, ...
Clinical Trials Arena on MSN
Neurocrine’s Phase III trial of valbenazine for DCP fails to meet endpoints
Neurocrine Biosciences has reported that its Phase III trial assessing the selective vesicular monoamine transporter 2 (VMAT2) inhibitor, valbenazine, for dyskinetic cerebral palsy in paediatric and ...
Shock rippled through Dorset as inquest evidence suggested that a 76-year-old British man killed his terminally ill wife before taking his own life, revealing profound caregiving strain and unanswered ...
An experimental gene therapy seems to slow the progression of Huntington’s disease by about 75 per cent, and researchers are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback